Prolonged pegylated liposomal doxorubicin treatment for recurrent pelvic cancers: a feasibility study.
We conducted a proof of concept study evaluating prolonged treatment with pegylated liposomal doxorubicin for recurrent ovarian, tubal and peritoneal carcinoma. Thirteen consecutive patients received an average of 22.6 cycles of pegylated liposomal doxorubicin, with an average cumulative dose of 1409 mg/m(2) . Progression-free survival at 18 months was 61.5%, and was longer than the previous progression-free survival in 10 of the 13 patients. Overall 5-year survival was 78.8%. Despite prolonged use and relatively large cumulative doses of pegylated liposomal doxorubicin, most of the patients had mild to moderate side-effects, none of the patients had detectable cardio-toxic side-effects, and a positive impact on the performance status was noticed. Thus, in our group of patients, continued pegylated liposomal doxorubicin treatment was associated with a longer progression-free interval and allowed improved performance status with manageable toxicity.
Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, Lady Davis Research Institute, Montreal, Quebec, Canada.
Alex
http://orcid.org/0000-0001-8712-9197
A
Rabinovich
Division of Cancer Epidemiology, Department of Oncology, McGill University, Montreal, Quebec, Canada.
Agnihotram V
AV
Ramanakumar
Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, Lady Davis Research Institute, Montreal, Quebec, Canada.
Susie
S
Lau
Division of Gynecologic Oncology, Segal Cancer Center, Jewish General Hospital, Lady Davis Research Institute, Montreal, Quebec, Canada.
Walter H
WH
Gotlieb
D000368:Aged; D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use*; D018394:CA-125 Antigen / Q000097:blood; D002277:Carcinoma / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D015331:Cohort Studies; D004317:Doxorubicin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005185:Fallopian Tube Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000601:surgery; D011092:Polyethylene Glycols / Q000627:therapeutic use
D000903:Antibiotics, Antineoplastic; D018394:CA-125 Antigen; C506643:liposomal doxorubicin; D011092:Polyethylene Glycols; D004317:Doxorubicin
Recurrent ovarian carcinoma; pegylated liposomal doxorubicin; prolonged treatment